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ABSTRACT: Introduction: Collagen cross-linking is a key param-
eter in extracellular matrix (ECM) maturation, turnover, and
stiffness. We examined aspects of collagen cross-linking in
dystrophin-deficient murine, canine, and human skeletal muscle.
Methods: DMD patient biopsies and samples from mdx mice and
golden retriever muscular dystrophy dog samples (with appropri-
ate controls) were analyzed. Collagen cross-linking was eval-
uated using solubility and hydroxyproline assays. Expression of
the cross-linking enzyme lysyl oxidase (LOX) was determined by
real-time polymerase chain reaction, immunoblotting, and immu-
nofluorescence. Results: LOX protein levels are increased in dys-
trophic muscle from all species evaluated. Dystrophic mice and
dogs had significantly higher cross-linked collagen than controls,
especially in the diaphragm. Distribution of intramuscular LOX
was heterogeneous in all samples, but it increased in frequency
and intensity in dystrophic muscle. Conclusion: These findings
implicate elevated collagen cross-linking as an important compo-
nent of the disrupted ECM in dystrophic muscles, and heightened
cross-linking is evident in mouse, dog, and man.
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There are currently 41 documented forms of mus-
cular dystrophy caused by monogenic mutations.1
Many result in progressive deterioration of func-
tional musculature and its replacement by non-
contractile fibrotic tissue.2 Duchenne muscular dys-
trophy (DMD), an X-linked disease caused by dis-
ruption of the dystrophin gene, is one of the most
common forms, affecting 1 in 4,000 boys.3 It is
characterized by a progressive loss of muscle func-
tion.2 Dystrophin-deficient muscles are vulnerable
to contraction-induced damage, which leads to
repeated cycles of necrosis and regeneration that
result in failed regeneration, increased fibrosis,
and progressive loss of muscle function.2,4 In DMD
patients, this results in loss of ambulation, severe
muscle contractures, and, without support devices,
eventual loss of ventilatory function, leading to
premature death.5,6 Understanding the pathophysi-
ology of the associated fibrosis is critical for identi-
fication of novel and optimized therapeutic targets
to improve both quantity and quality of life in
affected individuals.
Within skeletal muscle, the extracellular matrix
(ECM) is dually important for providing a cellular
scaffold and transmitting muscle contractile
forces.7,8 However, the pathological accumulation
of ECM that occurs in fibrosis impairs normal cell
function and force transmission, as well as inhibi-
ting repair and regeneration, thereby compound-
ing the primary cellular defect. The vast majority
of research toward countering fibrosis in muscular
dystrophy has targeted pathways involved in patho-
logic collagen production, primarily the transform-
ing growth factor (TGF)-b-Smad2/3 signaling
pathway.9 These strategies may prevent fibrosis, but
they may also alter the normal physiologic scaffold-
ing properties of the ECM.
Although increased stiffness is often associated
with fibrotic muscles,10,11 we recently reported that
total muscle collagen content does not correlate
with tissue stiffness in mdx mice.12 These data sug-
gest that posttranslational modifications of colla-
gen, such as collagen cross-linking, are critical
parameters in dystrophic muscle pathology. Fibril-
lar collagens make up most of the collagen in skel-
etal muscle and are the primary load-bearing
structures within the ECM.13,14 Fibrillar collagen
a-chains form a triple helix that is secreted in a
pro-form, cleaved, and cross-linked into non-reducible
collagen fibrils. The mechanical strength of collagen
fibrils is highly dependent on the extent of cross-link
formation.15
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Collagen is dramatically overexpressed in fibrotic
muscle tissue,10,16 and its content is inversely corre-
lated with muscle strength in dystrophy.17 Little is
known about the extent of posttranslational modifi-
cations, including cross-linking in dystrophic muscle.
The initial step in collagen cross-linking requires lysyl
oxidase (LOX, or family members LOXL1–LOXL4)
to prime lysines and hydroxylines on collagen to
produce mature pyridinoline cross-links.18 Extent of
LOX expression has been highly associated with tis-
sue fibrosis and stiffness in multiple tissues, including
the heart.19 Indeed, LOX is among the most highly
upregulated genes in the myocardium and limb mus-
cle of the mdx mouse, a model of DMD.20 Because
cross-linked collagen is more resistant to proteoly-
sis,21 extensively cross-linked collagen may contribute
to irreversible scar formation. Therefore, collagen
cross-linking may be a critical factor in determining
fibrotic tissue stiffness in contrast to the content of
collagen in fibrotic lesions in DMD. The goals of this
study were to clarify the association between LOX lev-
els and collagen cross-linking in dystrophic muscle
and to determine if indices of heightened cross-
linking exist in animal models for DMD and DMD
patients.
METHODS
Animals. The University of Pennsylvania Animal
Care Committee approved the experiments in this
study. Six- and 18-month-old male C57 and mdx mice
were euthanized, and the tibialis anterior (TA) mus-
cle and the diaphragms were dissected. They were
either flash frozen in liquid nitrogen for biochemical
analysis or embedded in OCT and frozen in melting
isopentane for histological evaluation. Portions of TA
and diaphragm were collected from 1-year-old
golden retriever muscular dystrophy (GRMD) dogs
(n5 3) and an unaffected dog (n5 1) following
unrelated terminal endpoints and were either
flash frozen or frozen in OCT. Samples were stored
at –80 8C until further analysis.
Human Biopsy Samples. Samples of human quadri-
ceps muscle (n5 3) were obtained from the Well-
stone Muscular Dystrophy Cooperative Research
Center, Tissue and Cell Repository at the University
of Iowa, Carver College of Medicine (Iowa City,
Iowa). The DMD patients were between 5 and 8
years of age, and control patients between 8 and 13
years of age at the time of biopsy.
Gene Expression Analysis. Total RNA was isolated
from murine and canine muscles using TRIzol
reagent (Invitrogen) treated with DNase (Promega)
and reverse transcribed to cDNA using the GeneAmp
RNA polymerase chain reaction (PCR) kit (Applied
Biosystems) using the manufacturer’s directions.
Real-time PCR (Model 7300; Applied Biosystems) was
conducted on the resulting cDNA with Power SYBR
Green Master Mix (Applied Biosystems). Expression
levels of Lox (accession numbers: mouse, NM_010728;
dog, XM_538599), Loxl2 (mouse, XM_006519744),
and Col1a2 (mouse, NM_007743; dog, NM_001003187)
were determined with 18S expression serving as the
reference housekeeping gene.
Immunoblotting. Flash-frozen murine and canine
muscle tissue was finely crushed and homogenized in
tissue protein extraction reagent (T-PER; Thermo
Scientific) supplemented with protease and phospha-
tase inhibitor cocktails (Thermo Scientific). Quadri-
ceps biopsy samples from healthy males and DMD
patients (pooled from 25 10-mm frozen sections from
each patient) were lysed in radioimmunoprecipita-
tion assay (RIPA) buffer supplemented with protease
and phosphatase inhibitor cocktails (Sigma-Aldrich).
Protein concentration was measured using the
Bradford method (Bio-Rad). Samples were separated
by sodium dodecylsulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) on Tris-HCl-polyacrylamide
gels (Bio-Rad) and transferred to polyvinylidene fluo-
ride (PVDF) membranes. Membranes were blocked
with 5% milk in Tris-buffered saline and Tween 20
(TBST) and incubated in primary antibody diluted in
2% milk–TBST overnight at 4 8C, using anti-LOX
(Abcam ab31238; 1:500) for human and canine
samples and anti-LOX (Novus NBP2-24877; 1:500)
for mouse samples. The membranes were washed,
incubated in anti-rabbit horseradish peroxidase
(HRP)–conjugated secondary antibody (Cell Signaling
Technologies), and visualized using ECL Plus reagents
(Thermo Scientific) and autoradiography film (BioEx-
press). To provide loading controls, membranes
were stripped and either reprobed for glyceraldehyde
3-phosphate dehydrogenase (GAPDH; sc-25778;
1:2,000; Santa Cruz Biotechnology) or stained with
Coomassie Blue (Bio-Rad) or Ponceau S (Sigma-
Aldrich) solution for visualization.
Collagen Stability. A collagen solubility assay was
adapted22,23 to quantify the proportion of mature
cross-linked collagen from non–cross-linked and
immature cross-linked collagen. Briefly, flash-
frozen muscle tissue was ground using a mortar
and pestle over dry ice and then weighed. The tis-
sue was washed in 1ml of PBS and stirred for 30
minutes at 4 8C before centrifuging at 16,000g for
30 minutes at 4 8C. Non–cross-linked collagen was
digested in a 1:6 (weight:volume) solution of 0.5M
acetic acid with 1mg/ml pepsin, stirring overnight
at 4 8C. After centrifuging at 16,000g for 30
minutes at 4 8C, the supernatant was collected as
the pepsin-soluble fraction (PSF), and the pellet
was kept as the pepsin-insoluble fraction (PIF). For
the PSF, a 1:1 volume of 4M NaCl was added and
stirred for 30 minutes at 4 8C. The PSF was then
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centrifuged at 16,000g for 30 minutes at 4 8C, and
the supernatant was discarded. The collagen
contents of the PSF and PIF were then determined
by a hydroxyproline assay.
Hydroxyproline Assay. A hydroxyproline assay was
performed to quantify collagen content in both
the PSF and PIF, as described in previous stud-
ies.12,24 The samples were hydrolyzed overnight in
0.5ml of 6M hydrochloric acid at 105 8C. 10 ll of
hydrolysate were mixed with 150 ll isopropanol fol-
lowed by 75 ll of 1.4% chloramine-T (Sigma, St.
Louis, Missouri) in citrate buffer and oxidized at
room temperature for 10 minutes. The samples
were then mixed with 1ml of a 3:13 solution of
Ehrlich reagent [1.5 g of 4-(dimethylamino)benzal-
dehyde (Sigma), 5ml ethanol, and 337 ll sulfuric
acid] to isopropanol and incubated for 45 minutes
at 55 8C. Quantification was determined by extinc-
tion measurement of the resulting solution at
558 nm. A standard curve (0–1,000 lM, trans-
4-hydroxy-L-proline; Sigma) was included in each
assay. Results are reported as micrograms of hydrox-
yproline per milligram of tissue wet weight.
Picosirius Red Staining. Frozen OCT-embedded
GRMD samples were sectioned at 10mm, and Picosir-
ius red staining was performed as previously
described.12 Briefly, sections were fixed in 4% para-
formaldehyde for 10 minutes, rinsed, air dried,
stained for 1 hour in 0.1% (wt/vol) Sirius red
(Sigma-Aldrich), dissolved in saturated aqueous pic-
ric acid (Sigma-Aldrich), washed in 2 changes of
0.5% acetic acid, dehydrated in 3 changes of 100%
ethanol, cleared with Citra Solv, and mounted with
Cytoseal. The resulting slides were viewed under cir-
cularly polarized light scope (DMLP; Leica), rotating
polarizer, rotating analyzer, and dual quarter wave
plates on a camera system (Micropublisher 5.0; Q
Imaging).
Immunofluorescence. Acetone-fixed 10-mm sections
of mouse, dog, and patient muscle were incubated
overnight at 4 8C with anti-LOX (Abcam ab31238;
1:500) and anti-vimentin (Novus MB300; 1:800) pri-
mary antibodies using 5% bovine serum albumin
(BSA)–PBS with 0.1% Triton X-100 as a blocking solu-
tion/diluent. Alexa 568–conjugated anti-rabbit IgG
(Molecular Probes; 1:500) and Alexa 488–conjugated
anti-chicken IgY (Jackson; 1:500) secondary antibodies
were used. Slides were mounted using VectaShield
with 40,6-diamidino-2-phenylindole (DAPI; Vector
Labs) and imaged using the confocal microscope
(Model TSC-SP8; Leica). Quantification of human
LOX immunoreactivity was achieved by analysis of
5 independent fields of view (203) from control
(n5 3) and DMD patient (n5 3) quadriceps sections
using SMASHmuscle image analysis software.25
Statistical Analysis. All results are presented as
mean6 SEM unless otherwise stated. Statistical
analysis of the mouse data was performed by 2-way
analysis of variance using genotype and muscle
followed by a Bonferroni post hoc test comparing
genotypes within muscles and muscles within a
genotype. For the human samples, a Student t-test
was used to compare muscles from unaffected to
DMD subjects. For the dog samples there was only
a single control dog, so only a paired Student t-test
was performed between muscles of GRMD dogs.
P< 0.05 was considered statistically significant.
RESULTS
LOX and Collagen Cross-Linking Is Increased in mdx
Diaphragm. Gene expression of the collagen cross-
linking enzyme LOX was evaluated at the ends of
the mouse phenotypic spectrum by comparing a
less affected limb muscle (TA) and the more
severely affected diaphragm muscle of mdx mice at
age 6 months to age-matched C57 mice (Fig. 1A).
Although Lox expression was not significantly dif-
ferent between the wild-type and dystrophic TA, it
was significantly elevated in the diaphragms of mdx
mice. Accordingly, Col1a2 expression was also
highly upregulated in the mdx diaphragm; how-
ever, expression of the LOX family member, Loxl2,
was unchanged across the samples. At the protein
level (Fig. 1B), LOX abundance was similarly
increased in the mdx diaphragms at age 6 months
compared with those of C57 mice and was also sig-
nificantly higher in the dystrophic TA.
The consequence of higher levels of LOX was
evaluated with a collagen solubility assay, where the
soluble, insoluble, and total collagen levels were
determined in mdx and control muscles (Fig. 1C).
The amount of soluble collagen, representing non–
cross-linked and immature cross-linked collagen, was
similar between all muscles analyzed and represented
a minor proportion of the total collagen pool. In
contrast, 6-month mdx diaphragms had significantly
more mature cross-linked insoluble collagen and
total collagen than the mdx TA and age-matched C57
diaphragms. To determine whether there was an age-
dependent increase in either LOX or collagen,
muscles from 18-month-old mdxmice were compared
with those from 6-month-old animals. LOX levels
were similar between the 2 ages, but the mdx dia-
phragm continued to accrue insoluble collagen (Fig.
1D), whereas the TA insoluble content remained
unchanged (data not shown). These data demon-
strate that LOX is chronically elevated in the dystro-
phic mouse diaphragm, which results in progressive
accumulation of cross-linked collagen.
Increased Cross-Linking Features in GRMD Muscle. Due
to the relatively mild phenotype of the mdx mouse
compared with DMD patients, we also investigated
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LOX levels and collagen cross-linking in the more
severe GRMD dog model of DMD. Like the mdx
mouse, GRMD exhibits differential disease severity
between limb muscles and the diaphragm. Similar
to our findings in the mdx mouse, GRMD dia-
phragm displayed high upregulation of both LOX
and COl1A2 gene expression over control dog
levels, with no change in the TA (Fig. 2A). LOX
protein, although not detectable in control dog sam-
ples by Western blotting, was observed in GRMD sam-
ples, where its abundance among GRMD diaphragms
was consistently higher than the dog-matched
TA (Fig. 2B). Accordingly, GRMD diaphragms also
contained more insoluble and total collagen than all
other samples (Fig. 2C), in agreement with the find-
ings in mice described above.
As previously performed on mdx mouse muscle,12
the collagen density of GRMD muscle sections was
FIGURE 1. Lox expression and collagen cross-linking in the mdx
murine model of DMD. (A) Lox transcript level is increased in mdx
muscle (n5 7) over control (n5 6). Col1a2 is increased in mdx
muscles (n5 7) over control (n5 6), and in mdx diaphragm over
TA. Loxl2 tends to be upregulated in mdx muscles (n5 3) over
control (n53). (B) Representative portion of immunoblot for LOX
(32 kDa) with Ponceau stain for loading control. LOX protein is
increased inmdx (n53) over control (n5 3), withmdx diaphragm
higher than TA. (C) Soluble hydroxyproline content, representing
non–cross-linked or immature cross-linked collagen, of mdx
(n56) muscles are not different from C57 (n5 6). Insoluble
hydroxyproline content, representing cross-linked collagen, and
total collagen are increased in mdx, with mdx diaphragm higher
than control diaphragm or mdx TA for both insoluble and total col-
lagen. (D) Immunoblot of mdx diaphragm for LOX shows no addi-
tional increase at 18 months (n5 2) compared with 6 months.
Insoluble cross-linked collagen is higher at 18 months (n52)
compared with 6 months in mdx diaphragm. Significantly different
post-hoc test, indicated by *P<0.05 and **P<0.01, between
genotypes of same muscle; †P<0.05 and ††P<0.01, between
muscles of the same genotype; and #P<0.05, between ages of
mdx diaphragm.
FIGURE 2. LOX expression and collagen cross-linking in the
GRMD dog model of DMD in limb and diaphragm muscle. (A)
Transcriptional level of LOX and COL1A2 are dramatically
increased in GRMD diaphragm. (B) Immunoblot for LOX (32
kDa) using GAPDH (37 kDa) as a loading control from wild-
type and GRMD dogs. Protein level of LOX is not observable in
wild-type dogs, but is present in GRMD muscles, with dia-
phragm consistently higher than dog matched TA. (C) Soluble
hydroxyproline content, representing non–cross-linked collagen
or immature cross-linked collagen, does not show a consistent
difference between wild-type and GRMD. Insoluble hydroxypro-
line content, representing cross-linked collagen, is highest in
the GRMD diaphragm. Total collagen content is highest in the
GRMD diaphragm. Data are from 3 GRMD dogs and 1 control
dog. (D) Representative images of GRMD dog TA and dia-
phragm muscles viewed under circularly polarized light. Birefrin-
gent fibrillar collagen is visible with loosely (green), moderately
(yellow), and densely (red) packed collagen. Scale bar5 50 lm.
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visualized under circularly polarized light (Fig. 2D).
In accordance with the biochemical data described
above, the GRMD TA contained mostly loosely
packed collagen bundles (visualized as green), with
an extensive perimysial layer, whereas the diaphragm
collagen bundles were largely intermediate (yellow)
or densely (orange to red) packed, verifying that col-
lagen density is increased in GRMD diaphragm com-
pared with limb muscle. It is also notable that, in the
GRMD diaphragm, unlike the TA, the robust endo-
mysial expansion resulted in a lack of distinction
between endomysial and perimysial stromal regions.
Thus, the canine model of DMD also displays height-
ened indices of collagen cross-linking in the dia-
phragm as compared with less affected limb muscle.
LOX Localization Is Altered in Dystrophic
Muscle. LOX cross-linking activity occurs in the
ECM, but many different cell types can produce
this enzyme, including fibroblasts and muscle
fibers.19,26–28 To determine the distribution of
excess LOX in dystrophic muscle, immunofluores-
cence of LOX and vimentin, a marker of mesen-
chemyl cells, including fibroblasts, was performed.
In healthy muscle, LOX was evident in sparse
puncta associated with the ECM. For the mouse dia-
phragm, these areas were observed along the epi-
mysium and also in small foci in the perimysium
and perivascular areas (Fig. 3A and B). Approxi-
mately 2–5 LOX-positive regions were observed per
cross-section. The same infrequent LOX locations
were observed in the wild-type mouse TA (data not
shown). For the diaphragm of an unaffected dog
(Fig. 3C) the trend was similar. Of particular inter-
est were muscle fibers that were positive for LOX
both inside and outside of the sarcolemma, suggest-
ing that the muscle fiber itself was producing LOX
(Fig. 3C, inset). Dystrophic muscles from both spe-
cies exhibited similar LOX “hot spots,” but these
were more extensive both in number and in size
(Fig. 3D). This included more pronounced distri-
bution of LOX along the endomysium, evident in
the mdx TA muscle. Taken together, the expanded
distribution of LOX in mdx and GRMD muscle sec-
tions was consistent with the increased LOX tran-
script and protein levels found in dystrophic
muscles.
LOX is Increased in DMD Patient Muscle. To sub-
stantiate the translational value of our animal model
data, we measured LOX protein in quadriceps
biopsy samples from unaffected control subjects and
DMD patients by Western blotting (Fig. 4A). LOX
protein abundance was increased 3-fold in DMD
samples. Similar to the mouse and dog tissue, immu-
nofluorescence of unaffected control human
muscle demonstrated infrequent LOX-positive loci,
which were primarily located near the perimysial
regions (Fig. 4B). In DMD tissue, LOX again had a
broader distribution that included more frequent
foci observed in both endomysial and perimysial
regions. Quantification of the LOX-positive area
FIGURE 3. Confocal microscopic immunofluorescent images of
lysyl oxidase (LOX; red), vimentin (green), and DAPI (blue) on
10-lm-thick cryosections. (A) C57 mouse diaphragm shows
epimysial focal regions of LOX as well as (B) perimysial regions
of focal LOX, shown in insets. (C) Unaffected dog diaphragm
demonstrates similar focal expression of LOX as C57 mice. (D)
Diaphragm and tibialis anterior (TA) samples from mdx mice and
GRMD dogs depict increased frequency of focal LOX regions and
endomysial LOX. Higher magnification outsets of (B) and (C) are
indicated by dotted square regions of the lower magnification
image. Scale bars525 lm, unless indicated otherwise.
Collagen X-Linking in DMD MUSCLE & NERVE July 2016 75
fraction confirmed our Western blotting results,
with a 3-fold increase compared with control sub-
jects. These data demonstrate that the muscles of
DMD patients have increased LOX content and dis-
tribution, likely contributing to the progressive
fibrotic replacement of muscle.
DISCUSSION
Skeletal muscle fibrosis is an excessive deposition
of ECM components and accompanies the chronic
damage that occurs in muscular dystrophy. Little is
known about how this aberrant ECM is organized in
fibrotic dystrophic muscle, but there is evidence that
posttranslational modification of the ECM may be
part of the dystrophic pathology. Previous measure-
ments of a rarely used chicken model of muscular
dystrophy have shown increased proportions of
high-molecular-weight collagen suggestive of
increased cross-linking.29 In addition, studies using
mdx mice demonstrated increased Lox expression in
heart and limb muscle20 and histological association
between LOX and fibrosis.17 We have now extended
these observations to show that LOX protein is
increased in DMD patient muscle, as well as in
mouse and dog DMD models. In dystrophic mouse
and dog diaphragm, where pathology is the most
severe,10 there is also more collagen cross-linking, as
demonstrated by the increased insoluble fraction of
collagen. Importantly, there was no increase in LOX
with age. Insoluble collagen content increased pro-
gressively in the mdx diaphragm, demonstrating the
negative implications of chronic LOX elevation. We
also demonstrated that the increase in LOX is con-
served across species with muscular dystrophy. Taken
together, we conclude that increased LOX leads to
extensive collagen cross-linking, which is an impor-
tant feature of DMDmuscle.
Although the mdx mouse is the most commonly
studied model of DMD, it does not typically develop
fibrosis in the limbs at a young age, and it has several
differences from the human disease.4,30 Lifespan is
only moderately affected in the mdx mouse, and,
although limb muscles undergo cycles of degenera-
tion and regeneration, there is relatively little fibrosis.
The mdx diaphragm most accurately reflects the mus-
cle pathology observed in DMD patients,10 thus it is
not surprising that our measurements of cross-linking
were also most prominent in the mdx diaphragm com-
pared with the TA muscles. This is consistent with our
previous observations of increased collagen packing
density in the mdx diaphragm.12 To determine
whether our results were consistent in a model that
more accurately exhibits features of DMD, we used
the GRMD dog model.31 GRMD dogs also exhibit
increased cross-linked collagen and increased LOX
levels, supporting collagen cross-linking as a major
feature of the disease that is maintained across spe-
cies. However, increased cross-linking was not evident
in the GRMD TA muscles. Part of the reason we could
not detect this difference, as one would expect for
larger mammals, is the presence of a very thick peri-
mysium layer that is found in both unaffected healthy
and dystrophic dog TA muscles. This layer is an
important structural component of limb muscles in
dogs and is cross-linked to a greater extent than the
rest of the ECM in this muscle. Consistent with this is
the localization of more densely packed collagen
within the TA perimysium compared with the endo-
mysium. As such, the collagen solubility measure-
ments of muscle homogenates where the perimysium
is the overwhelmingly dominant source of matrix
likely masks the changes that may have occurred in
the endomysial layer around the fibers. In contrast,
FIGURE 4. LOX in human DMD patients. (A) Immunoblot for
LOX (32 kDa) using Coomassie staining as a loading control
from quadriceps biopsies of control (n53) and DMD (n53)
patients. All lanes are on the same blot with intervening lanes
excluded. Quantification of LOX blots from human patients indi-
cates a significant increase in LOX expression of DMD patients
compared with unaffected controls. (B) Immunofluorescent con-
focal microscopy images of lysyl oxidase (LOX; red), vimentin
(green), and DAPI (blue) on 10-lm-thick cryosections from
human quadriceps muscle. Unaffected control muscle shows
infrequent LOX foci relative to DMD muscle. Area fractions are
quantified showing 5 regions of interest (circles) from each sub-
ject biopsy with averages (lines) from DMD (n5 3) and control
(n53) patients, demonstrating significantly increased LOX
staining in DMD muscle. Significant difference indicated by
*P<0.05 for LOX expression between human patient groups.
Scale bar, 50 lm.
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the GRMD diaphragm possessed more densely
packed collagen fibrils throughout the muscle,
which was accompanied by an increase in collagen
insolubility.
To verify that the elevation of LOX observed in
animal models is also a feature of DMD, human bio-
pies were examined. In agreement with the animal
models, LOX expression was shown to be elevated in
quantity as well as in frequency of “hot spots” with
high focal expression. This is also consistent with 3
published microarray studies in the Gene Expression
Omnibus database,32 which showed significant upreg-
ulation of LOX in DMD (P5 4.93 1027, GDS21433;
P5 6.8 1024, GDS302734; P5 4.73 1022, GDS56335.
Although we were not able to measure collagen cross-
linking in human samples directly, the increased
LOX levels suggest that muscle in DMD is more
extensively cross-linked as observed in animal
models.
Collagen cross-linking has been described as a
major factor in fibrosis of multiple tissues,36,37
including the heart.38 The role of collagen cross-
linking in the heart is of great clinical significance
in patients with DMD, as it also undergoes a
fibrotic response. Whereas Lox mRNA is known to
be increased in mdx cardiac muscle,20 LOX protein
levels and collagen cross-linking have not been
studied but should be a target of future investiga-
tion. Increased collagen cross-linking is thought to
lead to a stiffer ECM and tissue, as demonstrated
in the left ventricle of the fibrotic heart.38 How-
ever, recent reports of muscle stiffness in mdx mice
have shown relatively more stiffening of limb mus-
cle as opposed to the diaphragm,12 even though
cross-linking is most prevalent in the diaphragm.
Collagen content shows little correlation with
passive stiffness,12 but collagen cross-linking does
not account for additional variability in muscle
fiber bundle stiffness.39 This suggests that,
although collagen may be stiffer at the molecular
level, other parameters of collagen organization
dictate muscle stiffness at the tissue level. However,
this does not preclude the micro-stiffness of the
cross-linked collagen fibrils from playing a critical
role in the cellular response to collagen cross-
linking in fibrosis. LOX is critical to the integrity
of the developing diaphragm, as mice that lack
LOX often die perinatally from diaphragmatic her-
nias.40 Further, skeletal muscle development is dis-
rupted in LOX knockout mice independent of
skeletal or tendon defects, demonstrating a role
for LOX in this process.28 LOXL1–LOXL4 are also
capable of cross-linking collagen, but little is
known about their expression in muscle. The
LOXL1–LOXL4 family members have a conserved
domain responsible for catalyzing the initial reac-
tion in collagen cross-linking. Their distinct roles
are not well understood, but LOXL2 has been
shown to be upregulated in fibrotic tissue and
responsible for collagen cross-linking in fibrosis.37
Our initial investigation showed that LOXL2
expression is not significantly altered in dystrophic
muscle, providing supporting evidence for LOX
being the primary enzyme responsible for cross-
linking changes in dystrophic muscle. Critically, it
is well established that cross-linked collagen is
much less susceptible to turnover,21 thus implicat-
ing collagen cross-linking in the development of
progressive scar tissue formation that predominates
in muscles from DMD patients.
LOX is known to be produced by vascular cells,
including endothelial cells,26 smooth muscle,19
and fibroblasts,27 which are all muscle resident
cells; however, a recent report by Kutchuk et al.
suggested skeletal muscle is also a major contribu-
tor of LOX expression, in which myofiber LOX
secretion is a negative feedback switch for stromal
collagen production and TGF-b activity.28 Although
evidence of LOX production from a specific cell
type was not conclusive in our study, we observed
scattered stromal foci of LOX immunoreactivity
throughout muscle cross-sections, as well as evi-
dence of staining within muscle fibers. In healthy
muscle, these foci are typically localized to perimy-
sial and epimysial regions, which are points of
high mechanical stress in contracting muscle. The
increased frequency and intrafascicular presence
of LOX staining in dystrophic muscle could be
due to the increased mechanical burden experi-
enced by dystrophin-deficient muscle fibers from
reduced attachment to the ECM. Taken together,
these lines of evidence suggest LOX secretion into
the ECM region is likely regulated by myofiber
mechanical sensing, which leads to appropriate
ECM adaptation to stress stimuli in non-
pathological situations. Unfortunately, dystrophic
muscle fibers are impaired in their attachment to
the ECM independent of the extent of ECM accu-
mulation and/or cross-linking, thereby preventing
the shutdown of collagen and LOX production.
This scenario potentially results in continuous
endomysial ECM accumulation, which leads to
replacement of functional muscle with fibrosis, as
seen in DMD patients.41
These studies raise important questions regard-
ing the best therapeutic targets for fibrosis. If LOX
is critical for reducing TGF-b actions, then target-
ing it may cause rampant collagen production and
lead to increased fibrosis. However, if excessive
LOX activity on ECM collagen cross-linking is det-
rimental to muscle function, then LOX inhibition
may be beneficial to diseased muscles where
reduced stiffness may also lessen structural damage
to muscle fibers. Clinically, therapies that target
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LOX and LOX family member activity show prom-
ise in preventing lung and liver fibrosis37 and set a
precedent for trials to counter muscle fibrosis
using this strategy. However, the balance between
the extent of fibrosis and the proportion of cross-
linking is a major consideration with respect to the
therapeutic window for treatments. Because cross-
linked collagen is relatively stable and refractory to
remodeling,18 anti-fibrotic therapies may not
remove cross-linked collagen, yet they may gradu-
ally reduce overall levels of fibrosis. This could be
important if anti-fibrotic therapies are applied to
late-stage disease patients in whom considerable
cellular loss has occurred in the heart and dia-
phragm. At that disease stage, removal of all fibro-
sis could lead to herniation of the diaphragm and
aneurysms in the heart, both lethal consequences.
In that case, the cross-linked collagen would safe-
guard against these potentially life-threatening
events.
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